Search Results - "Cheang, Maggie C.U"

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2 by WU, Joyce, LEE, Cathy, GILKS, C. Blake, DUNN, Sandra E, YOKOM, Daniel, JIANG, Helen, CHEANG, Maggie C. U, YORIDA, Erika, TURBIN, Dmitry, BERQUIN, Isabelle M, MERTENS, Peter R, IFTNER, Thomas

“…The overexpression of the epidermal growth factor receptor (EGFR) and HER-2 underpin the growth of aggressive breast cancer; still, it is unclear what governs…”
Get full text

Molecular Characterization of Basal‐Like and Non‐Basal‐Like Triple‐Negative Breast Cancer by Prat, Aleix, Adamo, Barbara, Cheang, Maggie C.U., Anders, Carey K., Carey, Lisa A., Perou, Charles M.

“…Learning Objectives Contrast the definitions of TN and basal‐like. Describe the undistinguishable global gene expression patterns of non‐basal‐like TN tumors…”
Get full text

Breast Cancer Subtypes and the Risk of Local and Regional Relapse by Voduc, K David, Cheang, Maggie C U, Tyldesley, Scott, Gelmon, Karen, Nielsen, Torsten O, Kennecke, Hagen

“…The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer…”
Get full text

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype by CHEANG, Maggie C. U, VODUC, David, BAJDIK, Chris, LEUNG, Samuel, MCKINNEY, Steven, CHIA, Stephen K, PEROU, Charles M, NIELSEN, Torsten O

“…Purpose: Basal-like breast cancer is associated with high grade, poor prognosis, and younger patient age. Clinically, a triple-negative phenotype definition…”
Get full text

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes by PARKER, Joel S, MULLINS, Michael, QUACKENBUSH, John F, STIJLEMAN, Inge J, PALAZZO, Juan, MARRON, J. S, NOBEL, Andrew B, MARDIS, Elaine, NIELSEN, Torsten O, ELLIS, Matthew J, PEROU, Charles M, BERNARD, Philip S, CHEANG, Maggie C. U, LEUNG, Samuel, VODUC, David, VICKERY, Tammi, DAVIES, Sherri, FAURON, Christiane, XIAPING HE, ZHIYUAN HU

“…PURPOSE To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the…”
Get full text

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study by PRAT, Aleix, BIANCHINI, Giampaolo, BYAKHOW, Mikhail, BERMEJO, Begoña, ZAMBETTI, Milvia, VAZQUEZ, Federico, GIANNI, Luca, BASELGA, José, THOMAS, Marlene, BELOUSOV, Anton, CHEANG, Maggie C. U, KOEHLER, Astrid, GOMEZ, Patricia, SEMIGLAZOV, Vladimir, EIERMANN, Wolfgang, TJULANDIN, Sergei

“…We report a retrospective exploratory analysis of the association of the research-based prediction analysis of microarray 50 (PAM50) subtype predictor with…”
Get full text

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy by Prat, Aleix, Fan, Cheng, Fernández, Aranzazu, Hoadley, Katherine A, Martinello, Rossella, Vidal, Maria, Viladot, Margarita, Pineda, Estela, Arance, Ana, Muñoz, Montserrat, Paré, Laia, Cheang, Maggie C U, Adamo, Barbara, Perou, Charles M

“…Predicting treatment benefit and/or outcome before any therapeutic intervention has taken place would be clinically very useful. Herein, we evaluate the…”
Get full text

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers by Bergamino, Milana A, Morani, Gabriele, Parker, Joel, Schuster, Eugene F, Leal, Mariana F, López-Knowles, Elena, Tovey, Holly, Bliss, Judith M, Robertson, John F R, Smith, Ian E, Dowsett, Mitch, Cheang, Maggie C U

“…Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor-positive breast cancer. The impact of…”
Get full text

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial by CHEANG, Maggie C. U, DAVID VODUC, K, STIJLEMAN, Inge J, DAVIS, Carole, EBBERT, MarkT W, PARKER, Joel S, ELLIS, Matthew J, BERNARD, Philip S, PEROU, Charles M, NIELSEN, Torsten O, DONGSHENG TU, SHAN JIANG, LEUNG, Samuel, CHIA, Stephen K, SHEPHERD, Lois E, LEVINE, Mark N, PRITCHARD, Kathleen I, DAVIES, Sherri

“…Recent studies suggest that intrinsic breast cancer subtypes may differ in their responsiveness to specific chemotherapy regimens. We examined this hypothesis…”
Get full text

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients by Liu, Shuzhen, Chia, Stephen K, Mehl, Erika, Leung, Samuel, Rajput, Ashish, Cheang, Maggie C. U, Nielsen, Torsten O

“…Estrogen receptor status in breast cancer is associated with response to hormonal therapy and clinical outcome. The additional value of progesterone receptor…”
Get full text

Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival by CHEANG, Maggie C. U, TREABA, Diana O, NIELSEN, Torsten O, GOWN, Allen M, SPEERS, Caroline H, OLIVOTTO, Ivo A, BAJDIK, Chris D, CHIA, Stephen K, GOLDSTEIN, Lynn C, GELMON, Karen A, HUNTSMAN, David, BLAKE GILKS, C

“…Estrogen receptor (ER) expression predicts improved breast cancer-specific survival and reduced risk of recurrence and is targeted in breast cancer therapy. A…”
Get full text

Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization by Romero, Atocha, Martín, Miguel, Cheang, Maggie C.U, López García-Asenjo, José Antonio, Oliva, Belén, He, Xiaping, de la Hoya, Miguel, García Sáenz, Jose Ángel, Arroyo Fernández, Manuel, Díaz Rubio, Eduardo, Perou, Charles M, Llopis, Trinidad Caldés

“…Anthracyclines are frequently used for the treatment of breast cancer and topoisomerase II alpha ( TOP2A ) is considered to be the molecular target. Numerous…”
Get full text

Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer by RING, Brian Z, SEITZ, Robert S, ESTOPINAL, Noel C, ROSS, Douglas T, BECK, Rod, SHASTEEN, William J, TARR, Shannon M, CHEANG, Maggie C. U, YODER, Brian J, BUDD, G. Thomas, NIELSEN, Torsten O, HICKS, David G

“…Patients with breast cancer experience progression and respond to treatment in diverse ways, but prognostic and predictive tools for the oncologist are…”
Get full text

Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast Cancer by Crabb, Simon J, Cheang, Maggie C.U, Leung, Samuel, Immonen, Taina, Nielsen, Torsten O, Huntsman, David D, Bajdik, Chris D, Chia, Stephen K

“…Abstract Background Axillary lymph node involvement remains the most important prognostic factor in early-stage breast cancer. We hypothesized that molecular…”
Get full text

Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer by SO, Alan I, LEVITT, Randy J, EIGL, Bernhard, FAZLI, Ladan, MURAMAKI, Motosugu, LEUNG, Sam, CHEANG, Maggie C. U, NIELSEN, Torsten O, GLEAVE, Martin, POLLAK, Michael

“…Purpose: Insulin-like growth factor (IGF) binding proteins (IGFBP) modulate interactions of IGF ligands with the IGF-I receptor. The role of IGFBPs, and…”
Get full text

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer by Cheang, Maggie C. U., Chia, Stephen K., Voduc, David, Gao, Dongxia, Leung, Samuel, Snider, Jacqueline, Watson, Mark, Davies, Sherri, Bernard, Philip S., Parker, Joel S., Perou, Charles M., Ellis, Matthew J., Nielsen, Torsten O.

“…Background Gene expression profiling of breast cancer has identified two biologically distinct estrogen receptor (ER)-positive subtypes of breast cancer:…”
Get full text

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer by NIELSEN, Torsten O, PARKER, Joel S, CHEANG, Maggie C. U, MARDIS, Elaine R, PEROU, Charles M, BERNARD, Philip S, ELLIS, Matthew J, LEUNG, Samuel, VODUC, David, EBBERT, Mark, VICKERY, Tammi, DAVIES, Sherri R, SNIDER, Jacqueline, STIJLEMAN, Inge J, REED, Jerry

“…To compare clinical, immunohistochemical (IHC), and gene expression models of prognosis applicable to formalin-fixed, paraffin-embedded blocks in a large…”
Get full text

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression by Cheang, Maggie C.U., Martin, Miguel, Nielsen, Torsten O., Prat, Aleix, Voduc, David, Rodriguez‐Lescure, Alvaro, Ruiz, Amparo, Chia, Stephen, Shepherd, Lois, Ruiz‐Borrego, Manuel, Calvo, Lourdes, Alba, Emilio, Carrasco, Eva, Caballero, Rosalia, Tu, Dongsheng, Pritchard, Kathleen I., Levine, Mark N., Bramwell, Vivien H., Parker, Joel, Bernard, Philip S., Ellis, Matthew J., Perou, Charles M., Di Leo, Angelo, Carey, Lisa A.

“…Purpose. To determine intrinsic breast cancer subtypes represented within categories defined by quantitative hormone receptor (HR) and HER2 expression…”
Get full text

Use of mutation profiles to refine the classification of endometrial carcinomas by McConechy, Melissa K, Ding, Jiarui, Cheang, Maggie CU, Wiegand, Kimberly C, Senz, Janine, Tone, Alicia A, Yang, Winnie, Prentice, Leah M, Tse, Kane, Zeng, Thomas, McDonald, Helen, Schmidt, Amy P, Mutch, David G, McAlpine, Jessica N, Hirst, Martin, Shah, Sohrab P, Lee, Cheng-Han, Goodfellow, Paul J, Gilks, C Blake, Huntsman, David G

“…The classification of endometrial carcinomas is based on pathological assessment of tumour cell type; the different cell types (endometrioid, serous,…”
Get full text

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes by Parker, Joel S, Mullins, Michael, Cheang, Maggie C U, Leung, Samuel, Voduc, David, Vickery, Tammi, Davies, Sherri, Fauron, Christiane, He, Xiaping, Hu, Zhiyuan, Quackenbush, John F, Stijleman, Inge J, Palazzo, Juan, Marron, J S, Nobel, Andrew B, Mardis, Elaine, Nielsen, Torsten O, Ellis, Matthew J, Perou, Charles M, Bernard, Philip S

“…To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene…”
Get full text